Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV RO0503821 for correction of anemia in dialysis patients with chronic kidney disease
2004-001298-24Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2004
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta in anaemia (2 arms), sponsored by Roche. Primary endpoint: Efficacy of IV RO0503821 for correction of anemia. Started Jun 2004; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anaemia
Beyond the preview
Go deeper on 2004-001298-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001298-24.